Drug Search Results
More Filters [+]

PF-05206388

Alternative Names: pf-05206388, pf05206388, pf 05206388
Latest Update: 2022-08-22
Latest Update Note: Clinical Trial Update

Product Description

human embryonic stem cell derived retinal pigment epithelium

Mechanisms of Action: Cell Therapy

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: Intraocular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Moorfields Eye Hospital NHS Foundation Trust
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PF-05206388

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Macular Degeneration

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

B4711001

P1

Recruiting

Macular Degeneration

2023-10-10

Recent News Events

Date

Type

Title